Exact Sciences Corp. and Thrive Earlier Detection Corp. have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock consideration of up to $2.15 billion.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
